Strategies to improve anxiety and depression in patients with COPD: a mental health perspective

Athanasiou Tselebis1
Argyro Pachi1
Ioannis Ilias2
Epaminondas Kosmas3
Dionisios Bratis1
Georgios Moussas1
Nikolaos Tzanakis4,5

1Psychiatric Department, “Sotiria” General Hospital of Chest Disease, Athens, Greece; 2Endocrinology Department, “Elena Venizelou” Hospital, Athens, Greece; 3Pulmonary Department, “Metropolitan” General Hospital, Athens, Greece; 4Department of Thoracic Medicine, 5Social Medicine, Laboratory of Epidemiology, University of Crete Medical School, Heraklion, Greece

Abstract: Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease characterized by progressive and only partially reversible symptoms. Worldwide, the incidence of COPD presents a disturbing continuous increase. Anxiety and depression are remarkably common in COPD patients, but the evidence about optimal approaches for managing psychological comorbidities in COPD remains unclear and largely speculative. Pharmacological treatment based on selective serotonin reuptake inhibitors has almost replaced tricyclic antidepressants. The main psychological intervention is cognitive behavioral therapy. Of particular interest are pulmonary rehabilitation programs, which can reduce anxiety and depressive symptoms in these patients. Although the literature on treating anxiety and depression in patients with COPD is limited, we believe that it points to the implementation of personalized strategies to address their psychopathological comorbidities.

Keywords: COPD, anxiety, depression, pharmacological treatment, psychotherapy

Introduction
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines chronic obstructive pulmonary disease (COPD) as a disease state characterized by exposure to noxious agents resulting in airflow limitation that is not fully reversible, causing shortness of breath and significant systemic effects.1 This definition covers a spectrum of respiratory diseases, and includes both the clinical diagnosis of chronic bronchitis and the pathological diagnosis of emphysema.2 In clinical practice, COPD is defined by characteristically diminished air flow in lung function tests. Spirometry is required to make the diagnosis and staging in this clinical context;3 the presence of a postbronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) <0.70 confirms the presence of persistent airflow limitation and thus of COPD. Unlike asthma, the limitation is practically irreversible and usually worsens gradually over time.4 This worsening is causally related to an abnormal inflammatory response of the lungs to inhaled harmful particles or gases, attributed – usually – to smoking.5

COPD is a leading cause of morbidity and mortality worldwide and results in an economic and social burden that is both substantial and increasing.6 COPD prevalence, morbidity, and mortality vary across countries and across different groups within countries. The Global Burden of Disease Study estimated that COPD will become the fourth leading cause of death and the seventh leading cause of disability-adjusted life year(s) lost worldwide by 2030.7 The death rate associated with COPD has doubled in the past 30 years,8 implying that the health-care system failed to address the problem.9

Comorbidity studies10–12 from Western and developing countries, inpatient and outpatient population, and younger and elderly patients reveal a substantial overrepresentation of anxiety and depression in COPD, from significant symptoms to full...
diagnostic mental disorders, according to Diagnostic and Statistical Manual of Mental Disorders-4th edition (DSM-IV) and International Classification of Diseases, 10th Revision (ICD-10) taxonomic systems. Prevalence rates of both anxiety and depression in patients with COPD vary widely depending on the population surveyed and the measurement tools. Also, the overlap between symptoms of COPD disease and symptoms of anxiety and depression may contribute to the variations in prevalence figures, especially because questionnaires designed to screen for anxiety and depression include a large number of somatic complaints (poor sleeping pattern, anorexia, breathlessness, and fatigue).

Anxiety in COPD patients is often associated with clinical depression, and studies indicate that depressed COPD patients have a seven-fold risk to suffer from comorbid clinical anxiety compared to nondepressed COPD patients. There is an overlap in existing symptomatology between the two disorders, with fatigue, weight changes, sleep disturbance, agitation, irritability, and difficulty in concentrating appearing as common symptoms.

In outpatients with COPD, studies indicate rates of depression varying from 7% to 80% and that of anxiety from 2% to 80%. Prevalence of generalized anxiety disorder (GAD) ranges from 10% to 33% and of panic attacks or panic disorder (PD) from 8% to 67%. In stable COPD, the prevalence of clinical depression ranges from 10% to 42% and that of anxiety between 10% and 19%. In a systematic review that focused on patients with severe COPD disease, the prevalence of depression ranged from 37% to 71% and that of anxiety from 50% to 75%, figures comparable to or higher than prevalence rates in other advanced diseases such as cancer, HIV, heart disease, and renal disease.

Comorbid psychological impairments in COPD patients predict increased functional impairment, disability, and morbidity, lower quality of life, and decreased adherence to the treatment. A systematic review and a meta-analysis have shown that depression and anxiety increase the risk of hospitalization for COPD patients. Also, patients with comorbidity spend twice as long in hospitals and have increased mortality rates.

Accordingly, recent consensus statements and guidelines on optimal care for COPD patients emphasize the need for assessment and adequate treatment of persisting anxiety and depressive symptoms in these patients. Despite the high prevalence and considerable negative impact of coexisting psychopathology in COPD, the evidence about optimal approaches for managing depression and anxiety remains unclear and largely speculative.

The objectives of this paper are to provide an overview of the prevalence, impact, and pathophysiology associated with anxiety and depression in patients with COPD and to review studies on pharmacological and nonpharmacological interventions, in an effort to highlight current knowledge and identify needs for future research.

**Anxiety in patients with COPD**

Anxiety disorder is a generalized term for a variety of abnormal and pathological fear and anxiety states, including GAD, PD, agoraphobia, obsessive–compulsive disorder, phobic disorders, and traumatic stress disorders. Anxiety disorders are defined using established diagnostic criteria, eg, current versions of DSM or ICD criteria, while anxiety symptoms are assessed using formal psychological instruments, eg, Hamilton Anxiety Rating Scale, Beck Anxiety Inventory, and State–Trait Anxiety Inventory. GAD and PD occur at a higher rate in patients with COPD compared with the general population. Symptoms of anxiety are manifested in a variety of ways, including physiological signs of arousal, such as tachycardia, sweating, and dyspnea. Anxiety in patients with COPD is intimately linked with the fear of acute dyspnea attacks and essentially with the sense of suffocation and the fear of death.

The prevalence of anxiety-related disorders in COPD is associated with reduced functional ability and rehospitalizations. Common mechanisms for explaining this high association include factors related to smoking and dyspnea. Smoking is widely acknowledged as the most important environmental risk factor for the development of COPD, and high levels of anxiety have been identified as a risk factor for the initiation of smoking. Thus people who develop COPD as a consequence of smoking probably experienced higher levels of anxiety than the general population prior to developing the disease, and moreover, these individuals may have a greater tendency to addiction since nicotine withdrawal is associated with greater symptoms of anxiety.

Evidence also suggests pathophysiologic relationships among dyspnea, hyperventilation, and anxiety. Physiological research has demonstrated both that respiratory rate is increased by anxiety and that the resulting rapid, shallow breathing pattern markedly worsens dyspnea in COPD. The key common physiological factors in COPD are increased ventilatory load, reduced ventilatory capacity, and increased neural respiratory drive, hyperinflation, and neuromechanical dissociation, leading to an efferent–afferent mismatch, which is fundamental to the origin of dyspnea. When the sense of heightened effort increases beyond
a certain threshold and/or the dissociation between neural drive and the mechanical response reaches a critical level (which likely varies between individuals), it will generate a strong emotional reaction (ie, fear, distress, and anxiety) in the individual, which in turn will precipitate conditioned behavioral (avoidance) responses. These strategies help to attenuate neuromechanical dissociation and to allay anxiety. In some patients these compensations are not possible, and the affective response can quickly escalate to overt panic and overwhelming feelings of lack of control. Extreme fear and foreboding will, in turn, trigger patterned ventilatory and circulatory responses (via sympathetic nervous system activation) that can further amplify respiratory discomfort. The vicious cycle of breathlessness and anxiety conceptualized as “dyspnea–anxiety–dyspnea cycle” relationship suggests patients’ emotional response to breathlessness exacerbates their perception of breathlessness. This cycle can be illustrated by the cognitive behavioral model of dyspnea, hyperventilation, and anxiety. This positive feedback cycle states that individuals may misinterpret physical sensations such as dyspnea, leading to anxiety, further autonomic arousal, and increased dyspnea.

Other theories proposed to explain the overlap of anxiety and panic attack symptoms with COPD are the hyperventilation model and the carbon dioxide hypersensitivity model. Hyperventilation in excess of metabolic need leads to a decrease in pCO₂, causing a respiratory alkalosis that leads to vasoconstriction and typical panic symptoms such as light-headedness, numbness, tingling sensations, and shortness of breath, in healthy individuals. In COPD patients, increased frequency of breathing predisposes to dynamic hyperinflation, due to the slow time constant for lung deflation. Hyperinflation increases the elastic load, work, and effort of breathing, reduces inspiratory reserve capacities, and exacerbates dyspnea. In patients with severe COPD, chronic hypoventilation induces hypercapnia. An increase in pCO₂ levels has been shown to activate medullary chemoreceptors, which elicits a panic response by activating noradrenergic neurons in the locus ceruleus. Lactate acid, formed because of hypoxia is also linked to panic attacks, and evidence suggests that patients with both COPD and anxiety are hypersensitive to lactic acid and hyperventilation. In other words, the pathogenesis of panic may be related to respiratory physiology by several mechanisms: the anxiogenic effects of hyperventilation, the catastrophic misinterpretation of respiratory symptoms, and/or a neurobiologic sensitivity to CO₂, lactate, or other signals of suffocation. Consequently, there is a reason to believe that chronic pulmonary disease constitutes a risk factor for the development of panic anxiety related to repeated experiences with dyspnea and life threatening exacerbations of pulmonary dysfunction, repeated episodes of hypercapnia or hyperventilation, the use of anxiogenic medications, and the stress of coping with chronic disease.

Anxiety symptoms may distract patients from self-management of disease exacerbations. Even a low intensity dyspnea attack is able to trigger panic anxiety which in turn heightens the sensation of dyspnea and sense of suffocation, thus creating a vicious cycle that forces many patients to restrict their daily activities. Patients with COPD usually describe their understanding of acute dyspnea as an experience inextricably related to anxiety and emotional functioning. As a result, this comorbidity leads to significant decrease in functional capacity, including phobic avoidance of activity because of anticipatory anxiety, further deconditioning, and misuse of anxiogenic medications (β₂ agonists, theophylline, and oral corticosteroids).

Recognition of the presence of this pathophysiological mechanism provides a more comprehensive assessment of the additional functional impairment experienced by the patient even if biological parameters and laboratory results are insufficient to justify the compromised ability to perform physical functions. Sense of loss of control over the disease itself and loss of mastery over their ability to engage in personal and social activities engenders frustration and anxious feelings.

It is important to note that dyspnea at rest or on exertion does not correlate with the magnitude of anxiety-related symptoms, and furthermore, the magnitude of decrease in dyspnea with pharmacotherapy or exercise training is not associated with the reduction in anxiety-related symptoms, this indicates that there are other factors contributing to this relationship. Additionally, although patients with panic report more catastrophic misinterpretations of bodily symptoms, they do not differ from patients without panic on measures of physical functioning, disease severity, shortness of breath, or psychological distress. Thus, it has been suggested that panic symptoms may reflect a cognitive interpretation of pulmonary symptoms rather than objective pulmonary status.

Studies indicate that anxiety and depression were not correlated with COPD severity (as determined by FEV₁% of predicted), and it is reported that dyspnea ratings were influenced by anxiety and depressive symptoms, whereas the physiological state scarcely influenced the anxiety and depressive symptomatology. A possible explanation is that
patients construe disease seriousness subjectively, which contributes to the development of the levels of anxiety and depressive symptoms. 

Depression in patients with COPD

Today, the ICD-10 and DSM-IV criteria for depression are the most common diagnostic tools. Different subtypes of depression have been defined, and the clinical course of depression is acknowledged to be variable with patients moving in and out the diagnostic subtypes over time. When it comes to depression in patients with severe somatic illness, the validity of DSM criteria may to a certain degree be questioned because it is difficult to decide when somatic symptoms are secondary to depression, or when they are secondary to somatic illness. Severity of depression is determined by the number and level of symptoms, as well as the degree of functional impairment. Patients with COPD may have a spectrum of symptom severity ranging from short-term depressive symptoms or adjustment disorder with depressed mood to dysthymia up to major depression.

In a cluster of studies that have compared depressive disorders across various chronic illnesses, COPD patients suffer from depression with greater frequency and greater chronicity of mood symptoms. Also, few studies have reported that approximately two-thirds of COPD patients with depression have moderate-to-severe depression, and in one study, it was reported that approximately one-fourth of COPD patients had unrecognized subclinical depression.

Depression in patients with COPD is often marked by feelings of hopelessness and pessimism, reduced sleep, decreased appetite, increased lethargy, difficulties in concentration, social withdrawal, impairment in functional abilities and performing activities of daily living, poorer self-reported health, impaired self-management of disease exacerbations, and poor health behaviors. The correlation between depressed mood and disease severity is modest; but depression symptoms are important correlates of perceived self-reported physical disability and poorer quality of life. Guilty feelings stemming from the sense of burden patients impose to their environment, in combination with the responsibility they might think they have for the occurrence of the disease, especially concerning ex-smokers, aggravates depressive symptomatology.

According to studies, clinically significant levels of depression and anxiety were more prevalent in younger COPD patients, irrespective of clinical severity of COPD, perhaps because younger patients may find it difficult to come to terms with enforced changes in lifestyle, with this leading to increased psychological morbidity.

Recent studies suggest that depression in patients with COPD is a heterogeneous entity with multiple contributing etiologies including genetic predisposition, environmental losses and stressors, and direct damage to the brain mediated by the physiologic effects of chronic respiratory disease.

The genetic vulnerability plays a role in the eventual development of COPD in that adolescents and young adults who are depressed or have a history of depression are more likely to progress in their use of and dependence on nicotine. Smoking, COPD, and depression form a dynamic model of circular causality, with depression playing a role in the initiation and maintenance of smoking, smoking leading to the development of COPD, and COPD in turn contributing to the genesis of depression.

Evidence suggests that the appearance of major depression or depressive symptomatology in patients suffering from a chronic disabling general medical condition is common and justified as a “reaction” to the losses imposed by the illness in both symbolic order and real grounds. These losses may include functional impacts such as inability to carry out prior occupational activities, shifted roles within the family, and social constellation, but also an insult to self-image that patients experience with the change in their general physical condition and somatic functioning. Losses for patients with COPD increase with the gradual deterioration of the disease. Dyspnea is the most common and disabling symptom experienced by COPD patients and is inextricably associated with feelings of despair, helplessness, and alienation, resulting in the apparent loss of interest for life and other people.

By the very nature of the disease process, COPD is associated with chronic, if often subclinical, hypoxemia. Low arterial oxygen saturation has been shown to be associated with periventricular white matter lesions, which are also present in elderly patients with depression. Several authors have investigated the relationship between chronic hypoxemia and neuropsychological function, and the consequences of chronic hypoxemia include both impaired cognitive function and depression. Most studies of hypoxemia and depression arise from the sleep apnea literature where one of the primary identified sequelae of recurrent nocturnal hypoxemia is depressed mood.

Both depression and COPD have been associated with processes that jeopardize the microvasculature of the brain, and there is evidence for systemic inflammation and elevated biomarkers of oxidative damage. Although...
there are difficulties in quantification of inflammatory biomarkers, sTNFR-1 has shown a strong association with rates of depression in COPD patients. In the absence of prior comorbidity, systemic inflammation in COPD may result in depression and IL-6 appears to play a particularly important role in humans and in animal models of depression. A prospective cohort study indicated that the mean time elapsed between the diagnosis of COPD and the first episode of depression was 7.6 years. The long-term use of systemic corticosteroids has also been related to depression in COPD, but results are inconclusive.

Although smoking, hypoxia, and inflammation have potential impact on the prevalence of depression in COPD, the strongest predictors of depression among patients with COPD are their severity of symptoms and reported quality of life. The advantage to recognizing the interdependent relationship of these contributing factors is the corollary recognition that effective intervention in any one of them will have a cascading, positive impact on the others. Effectively targeting depression, lost functionality, or chronic hypoxemia will decrease morbidity in that dimension, and potentially in the others as well.

**Treatment**

Despite high prevalence rates and deleterious impact of comorbid anxiety and depression in COPD, only a limited number of studies have addressed its management, accounting for the absence of recommendations regarding their treatment in the updated GOLD guidelines. Only pulmonary rehabilitation (PR) is suggested as treatment option (evidence A), which is also available for only a small percentage of patients. The National Institute for Health and Care Excellence (NICE) has published clinical guidelines for the use of stepped approaches to psychological and/or pharmacological treatment of depression in people with long-term conditions. In recognition of the expanding knowledge and the clinical importance of this area, we attempted to summarize existing empirical evidence based on studies implementing pharmacological and nonpharmacological interventions to reduce clinical anxiety and depression in people with COPD.

**Method**

A literature search was conducted for studies examining the effect of anxiolytic and antidepressant medical treatment, cognitive behavioral therapy (CBT), PR, and other complex interventions on anxiety and depressive symptoms in COPD patients, using PubMed databases. Essential keywords were "chronic obstructive pulmonary disease" OR "COPD" AND "anxiety" OR "depression" to capture the target population. Intervention search terms comprised "medication" OR "pharmacological treatment" OR "SSRIs" OR "antidepressants" OR "TCAs" OR "SNRIs" OR "mirtazapine" OR "buspirone" OR "benzodiazepines" OR "psychological interventions" OR "cognitive behavioural therapy" OR "psychotherapy" OR "pulmonary rehabilitation" OR "group therapy" OR "complex interventions" OR "relaxation" OR "health education" OR "counselling" OR "behavioural interventions" OR "alternative treatments" OR "Tai Chi" OR "yoga".

**Eligibility criteria**

Studies for inclusion were required to be in the English language and meet participant, intervention, comparator, and outcome criteria, for studies of controlled comparative design. We also included nonrandomized studies such as clinical trials, crossover studies, observational studies, and relevant review articles and meta-analyses. Participants were adults (men and women of age ≥ 18 years), with a confirmed diagnosis of COPD as defined by the GOLD standard, who were treated for symptoms of anxiety and depression. Mode of interventions was pharmacological and nonpharmacological, and was aimed at reducing symptoms of anxiety and depression. The primary outcomes of interest were reduction in these symptoms following the administration of these interventions. The outcome was measured by changes from baseline anxiety and depression scores to posttreatment scores, employing validated psychological assessment instruments.

**Quality assessment**

The quality of included controlled comparative design studies was assessed by two authors independently with respect to the Critical Appraisal Skills Program checklists for risk of bias evaluation. The methodological quality of full-text articles was assessed employing checklists from the Scottish Intercollegiate Guidelines Network.

**Results**

Electronic database searches yielded 637 records with 438 remaining after removal of duplicates. From the initial title screenings, 253 potentially relevant articles were identified and their abstracts were subsequently reviewed. Of these, 167 were excluded as they failed to meet inclusion criteria. Seventy-two studies and 14 reviews were retrieved in full text for further assessment.
Overview and effects of pharmacological and nonpharmacological interventions on anxiety and depression in COPD

Tables 1–4 outline the characteristics of pharmacological and nonpharmacological interventions reported in the included studies. The results column describes the effects of interventions in narratives, thus enabling comparisons across various studies.

Pharmacological treatment

Management of depression and anxiety in COPD patients starts with the correct diagnosis. Many patients suffer transitory mood symptoms during respiratory exacerbations and there is no evidence that these time-limited symptoms require specific treatment. NICE guidelines advise that antidepressants should not be routinely prescribed for physically ill patients with subthreshold symptoms of depression or mild-to-moderate depression. Pharmacological therapy must be considered when major depression is diagnosed to avoid its long-term effects on overall disability. A recent study in USA reported that less than a third of COPD patients with major depression received appropriate treatment.

All antidepressants have similar effectiveness but mainly differ based on type and severity of side effects. Based on which chemicals in the brain they affect, the main categories are tricyclic antidepressants (TCAs), tetracyclic antidepressants, monoamine oxidase inhibitors, reversible inhibitors of monoamine oxidase, selective serotonin reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake inhibitors, noradrenergic and specific serotonergic antidepressants, norepinephrine and dopamine reuptake inhibitors, and melanergic antidepressants.

The choice of antidepressant depends on the pattern of depression, and it is useful to differentiate between early- and late-onset depression, because there is a distinct symptom profile that necessitates diverse treatment strategies. Late-onset depression or geriatric vascular depression after COPD diagnosis, caused by physiologic changes associated with COPD that have direct effect on brain’s vasculature, is characterized by more cognitive dysfunction, physical disability, limited insight, and psychomotor

Table 1 Pharmacological treatment for anxiety and depression in COPD patients

<table>
<thead>
<tr>
<th>Source</th>
<th>Study design</th>
<th>Sample size (n)</th>
<th>Comparison</th>
<th>Measurement instruments</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Momtaz et al</td>
<td>Placebo-controlled</td>
<td>n=50 stage III and IV COPD patients with depression and/or anxiety</td>
<td>Fluoxetine 20 mg for 3 months vs placebo</td>
<td>MADRS, HAM-A</td>
<td>Significant improvement in both anxiety and depression in MADRS and HAM-A scores after 3 months of treatment</td>
</tr>
<tr>
<td>He et al</td>
<td>RCT</td>
<td>n=120 patients with stable COPD and moderate or severe depression</td>
<td>Sertraline hydrochloride 50 mg/d for 6 weeks vs placebo</td>
<td>HAMD-17, 6MWD, CAT</td>
<td>Patients in the sertraline hydrochloride group showed more changes in the HAMD-17 scores and CAT score after treatment and 6MWD than in the placebo group</td>
</tr>
<tr>
<td>eiser et al</td>
<td>RCT</td>
<td>n=28 stable outpatients with COPD stage I and II and depression</td>
<td>Paroxetine 20 mg vs placebo for 6 weeks, unblinded paroxetine for 3 months</td>
<td>HADS, BDI, MADRS, SGRQ, 6MWD</td>
<td>Treatment produced no significant differences, although overall improvement in depression correlated with 6MWD. Five patients developed side effects.</td>
</tr>
<tr>
<td>Study</td>
<td>Design</td>
<td>n &amp; Characteristics</td>
<td>Intervention</td>
<td>Measures</td>
<td>Results/Findings</td>
</tr>
<tr>
<td>----------------------------</td>
<td>-------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Lacasse et al(^{17})</td>
<td>RCT</td>
<td>n=23 outpatients with COPD (average stage III), and significant depressive symptoms. 15 completed (I=8, C=7)</td>
<td>Paroxetine 20 mg vs placebo, for 12 weeks</td>
<td>GDS, SF-36, CRQ</td>
<td>Clinical and statistical improvement in emotional and mastery domains of CRQ. Nonsignificant improvement in GDS. Anxiety scores were not significantly reduced for the intervention as compared with placebo; however, power was very limited. SGRQ scores demonstrated a clinically relevant, but inconclusive effect, favoring placebo.</td>
</tr>
<tr>
<td>Subbe et al(^{16})</td>
<td>RCT</td>
<td>n=8 COPD patients, 4 with baseline anxiety</td>
<td>Citalopram 10-20 mg vs placebo, for 3 months and 1 week</td>
<td>HADS, SGRQ</td>
<td>7 completed trial, 4 responded to escitalopram treatment. 5 withdrew because of adverse side effects. 19 of those who refused treatment were still depressed.</td>
</tr>
<tr>
<td>Yohannes et al(^{14})</td>
<td>Single-blinded, open study</td>
<td>n=57 COPD patients stage II and III and depression. I=14 agreed to escitalopram, C=22 of those who refused treatment</td>
<td>Escitalopram for 6 months, 20 mg/d</td>
<td>GMS and MADRS, MRADL, BPQ</td>
<td>No significant difference between groups in response rate. Trend for escitalopram group to respond better than controls after 8 weeks (subjective report). Significantly more recovery from depression after 5 or more weeks on escitalopram.</td>
</tr>
<tr>
<td>Smoller et al(^{16})</td>
<td>Case series</td>
<td>n=COBD patients (severity not reported)</td>
<td>Sertraline (25–100 mg/d) for 4 weeks to 1 year</td>
<td>Not formally assessed</td>
<td>No significant difference between groups in response rate. Trend for escitalopram group to respond better than controls after 8 weeks (subjective report). Significantly more recovery from depression after 5 or more weeks on escitalopram.</td>
</tr>
<tr>
<td>Evans et al(^{48})</td>
<td>RCT</td>
<td>n=42 physically ill elderly depressed patients completed trial, 38 with respiratory diseases I=21, C=21</td>
<td>Fluoxetine vs placebo for 8 weeks, 20 mg/d</td>
<td>HAMD-17, ELDRS, GMS</td>
<td>No significant difference between groups in response rate. Trend for escitalopram group to respond better than controls after 8 weeks (subjective report). Significantly more recovery from depression after 5 or more weeks on escitalopram.</td>
</tr>
<tr>
<td>Papp et al(^{45})</td>
<td>Case series</td>
<td>n=6 consecutive COPD (severity not reported) outpatients</td>
<td>Sertraline titrated to 100 mg, for 6 weeks</td>
<td>Not formally assessed</td>
<td>No significant difference between groups in response rate. Trend for escitalopram group to respond better than controls after 8 weeks (subjective report). Significantly more recovery from depression after 5 or more weeks on escitalopram.</td>
</tr>
<tr>
<td>Singh et al(^{154})</td>
<td>Crossover study</td>
<td>n=11 stable COPD patients, at least stage II and STAI &gt;50 10 completed trial</td>
<td>Buspirone, 30–60 mg vs placebo, for 6 weeks</td>
<td>STAI, 12MWD</td>
<td>No significant differences in either exercise or anxiety scores. Reduced anxiety and depression. Increased 6MWD and WRmax. No improvement in depression, anxiety, or QoL scores. High rates of anticholinergic side effects.</td>
</tr>
<tr>
<td>Argyropoulou et al(^{153})</td>
<td>Double-blind crossover randomized trial</td>
<td>n=16 COPD patients, FEV(_{1})/FVC 50.7%±15.0% 10 completed trial</td>
<td>Buspirone 20 mg for 14 days</td>
<td>SCL-90-R, 6MWD and WRmax</td>
<td>Increased 6MWD and WRmax. No improvement in depression, anxiety, or QoL scores. High rates of anticholinergic side effects.</td>
</tr>
<tr>
<td>Ström et al(^{139})</td>
<td>RCT</td>
<td>n=26 stable COPD patients, at least stage II. Five completed trial I=14, C=12</td>
<td>Protriptyline vs placebo for 12 weeks, 10 mg/d</td>
<td>HADS, MACL, SIP</td>
<td>Improved outcomes for nortriptyline group in depression, anxiety, respiratory symptoms, physical comfort, and day-to-day functioning. No change in physiological measures.</td>
</tr>
<tr>
<td>Borson et al(^{177})</td>
<td>RCT</td>
<td>n=36 in patients with COPD stage II and III and comorbid depressive disorder. N=30, I=13, C=17 completed trial</td>
<td>Nortriptyline vs placebo for 12 weeks increased weekly until 1 mg/kg of body weight</td>
<td>CGI, HADS, PRAS, 12MWD, PFSI, SIP</td>
<td>Improved outcomes for nortriptyline group in depression, anxiety, respiratory symptoms, physical comfort, and day-to-day functioning. No change in physiological measures.</td>
</tr>
</tbody>
</table>

(Continued)
### Table 1 (Continued)

<table>
<thead>
<tr>
<th>Source</th>
<th>Study design</th>
<th>Sample size (n)</th>
<th>Comparison</th>
<th>Measurement instruments</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sharma et al&lt;sup&gt;37&lt;/sup&gt;</td>
<td>Double-blind method</td>
<td>n=10 consecutive COPD patients (all stages)</td>
<td>Imipramine-diazepam combination</td>
<td>Not formally assessed</td>
<td>Helped depressed patients recover faster, but diazepam may trigger respiratory failure</td>
</tr>
<tr>
<td>Light et al&lt;sup&gt;38&lt;/sup&gt;</td>
<td>RCT</td>
<td>n=12 outpatients with COPD stage III and high levels of depression, n=9 completed trial</td>
<td>Doxepin hydrochloride vs placebo for 6 weeks</td>
<td>BDI, 12MWD, STAI</td>
<td>No significant improvements in exercise capacity or depression and anxiety scores. Increase in 12MWD correlated with improvements in depression or anxiety</td>
</tr>
<tr>
<td>Gordon et al&lt;sup&gt;39&lt;/sup&gt;</td>
<td>RCT</td>
<td>n=13, stable COPD outpatients stage III, n=6 completed trial</td>
<td>Desipramine vs placebo for 8 weeks</td>
<td>BDI and Zung Self-rating Depression Scale</td>
<td>Depression scores improved significantly after treatment with placebo and with desipramine. No effect on physiological measures</td>
</tr>
</tbody>
</table>

**Abbreviations:** BAI, Beck anxiety inventory; BDI, Beck depression inventory; BDI-II, Beck depression inventory 1996 revision; HADS, Hospital Anxiety and Depression Scale; HAM-A, Hamilton Anxiety Rating Scale; HAMD-17, 17-item Hamilton Depression Rating Scale; MADRS, Montgomery and Asberg Depression Rating Scale; STAI, Spielberger's state-trait anxiety inventory; GDS, Geriatric Depression Scale; GMS, geriatric mental state; CGI, Clinical Global Improvement Scale; ELDRS, Evans Liverpool Depression Rating Scale; MACL, mood adjective checklist; BPQ, Breathing Problems Questionnaire; CRQ, Chronic Respiratory Questionnaire (COPD disease-specific QoL inventory); CAT, COPD assessment test; 6MWD, 6-minute walk distance; 12MWD, 12-minute walk distance; Wmax, maximum work-rate; PFI, Pulmonary Functional Status Instrument; PRAS, Patient-rated Anxiety Scale; WE, wellness education; FEV<sub>1</sub>, forced expiratory volume in 1 second; P/F, forced vital capacity.

### Table 2 Cognitive behavioral therapy in COPD patients

<table>
<thead>
<tr>
<th>Source</th>
<th>Study design</th>
<th>Sample size (n)</th>
<th>Comparison</th>
<th>Measurement instruments</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bove et al&lt;sup&gt;40&lt;/sup&gt;</td>
<td>RCT</td>
<td>I=33, C=33 Stage III-IV COPD outpatients with anxiety HADS-A ≥8</td>
<td>Minimal home-based CBT psychoeducative session in combination with a telephone booster session vs usual care</td>
<td>HADS-A, SGRQ, CRQ-M</td>
<td>Ongoing – currently recruiting participants</td>
</tr>
<tr>
<td>Howard and Dupont&lt;sup&gt;41&lt;/sup&gt;</td>
<td>RCT</td>
<td>I=112, C=110 COPD outpatients FEV&lt;sub&gt;1&lt;/sub&gt;/FVC &lt;0.7, MRC ≥3 with baseline anxiety and depression</td>
<td>Cognitive behavioral manual vs information booklets, at home over 5 weeks</td>
<td>HADS, CRQ-SR</td>
<td>At 6 months, there were significantly greater improvements in anxiety, depression, and dyspnea in the CBT intervention group</td>
</tr>
<tr>
<td>Jiang and He&lt;sup&gt;42&lt;/sup&gt;</td>
<td>RCT</td>
<td>I=49, C=47 Stage II–III COPD outpatients</td>
<td>Uncertainty management vs standard care: 4 sessions of 35 minutes, once per week over 4 weeks</td>
<td>SSAI, STAI, HADS-D</td>
<td>Compared to the control group, the intervention group showed significant improvement in anxiety, depression scores, and QoL</td>
</tr>
<tr>
<td>Kapella et al&lt;sup&gt;43&lt;/sup&gt;</td>
<td>RCT</td>
<td>N=23, I=9, C=9 Stage II COPD outpatients</td>
<td>6 sessions of CBT-I vs WE program</td>
<td>POMS-D, POMS-A</td>
<td>Significant positive treatment-related effects of the CBT-I intervention were noted for insomnia severity, global sleep quality, wake after sleep onset, sleep efficiency, fatigue, and beliefs and attitudes about sleep. Significant positive effects were noted for depressed mood after WE program</td>
</tr>
<tr>
<td>Study</td>
<td>Design</td>
<td>n (IR, C)</td>
<td>Intervention Details</td>
<td>Outcome Measures</td>
<td>Key Findings</td>
</tr>
<tr>
<td>------------------------------</td>
<td>--------</td>
<td>-----------</td>
<td>---------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Hynninen et al.</td>
<td>RCT</td>
<td>I=25, C=26</td>
<td>Stage II–III COPD outpatients with clinically significant anxiety and depression</td>
<td>CBT vs enhanced standard care: 7 sessions of 2 hours of group CBT over 7 weeks</td>
<td>CBT resulted in improvement in symptoms of anxiety and depression. The improvement was maintained at 8-month follow-up. In the control group, there was no significant change. Significant differences post intervention at 6-, 12-, and 18-month follow-ups, favoring the CBT group. At each follow-up, mean anxiety scores for the CBT group were in the nonclinical range, while mean scores for the routine care group were above the cutoff score. Intervention group showed lower symptoms of anxiety and depression and improved QoL measures compared to control group. CBT or COPD education, significantly improved QoL, anxiety, and depression over 8 weeks; the rate of change did not differ between groups. Improvements were maintained with no significant change during follow-up. Compared with UMC, CST produced lower scores on perceived stress, anxiety, depressive symptoms, and negative affect and improved scores on mental health functioning, optimism, vitality, and perceived social support. G1 and G2 patients improved in anxiety and depression as well as SGRQ and exercise tolerance. G3 improved in anxiety.</td>
</tr>
<tr>
<td>Livermore et al.</td>
<td>RCT</td>
<td>I=21, C=20</td>
<td>Stage II–III COPD outpatients attending PR program</td>
<td>CBT vs routine care: 4 individualized 1-hour sessions and strategies effective for the prevention and treatment of panic disorder</td>
<td></td>
</tr>
<tr>
<td>Lamers et al.</td>
<td>RCT</td>
<td>I=96, C=91</td>
<td>COPD outpatients with mild-to-moderate major depression</td>
<td>Minimal psychological intervention (4 individualized 2 hours CBT and skills training) vs usual care</td>
<td></td>
</tr>
<tr>
<td>Kunik et al.</td>
<td>RCT</td>
<td>I=118, C=120</td>
<td>Stage II–III COPD stable outpatients with baseline anxiety and depression</td>
<td>CBT vs COPD education: Intervention: 8×1 hour CBT group sessions, control: 8×1 hour COPD education sessions</td>
<td></td>
</tr>
<tr>
<td>Blumenthal et al.</td>
<td>RCT</td>
<td>I=158, C=170</td>
<td>Patients with end-stage lung disease awaiting lung transplantation</td>
<td>12 weeks of 30-minute telephone-based CST vs UMC</td>
<td></td>
</tr>
<tr>
<td>de Godoy et al.</td>
<td>RCT</td>
<td>n=49 (G1 =19, G2 =16, G3 =14) consecutive patients with COPD stage II and III. Mild-to-moderate levels of anxiety and depression</td>
<td>12-week treatment. G1: PRP (physical exercise, individual psychotherapy sessions, group educational sessions, physical therapy); vs G2:PRP without physical exercise; vs G3: PRP without psychotherapy</td>
<td>BAI, BDI, SGRQ</td>
<td></td>
</tr>
<tr>
<td>de Godoy and de Godoy</td>
<td>RCT</td>
<td>n=30 patients stage I–II COPD, attending PR program</td>
<td>PR (12-week treatment program) with psychotherapy vs PR without psychotherapy</td>
<td>BAI, BDI</td>
<td>Including psychotherapy significantly reduced patients’ anxiety and depression levels but did not modify 6MWD performance.</td>
</tr>
<tr>
<td>Kunik et al.</td>
<td>RCT</td>
<td>I=21, C=27</td>
<td>From veteran hospital stage II–III stable COPD outpatients</td>
<td>CBT vs COPD education: 1×2-hour session of group CBT vs education session lasting 2 hours</td>
<td>Statistical improvement in BAI and GDS.</td>
</tr>
<tr>
<td>Emery et al.</td>
<td>RCT</td>
<td>N=79 (EXESM =29; ESM =25; WL =25) COPD outpatients stage III</td>
<td>EXESM: 37 exercise sessions, 16 education sessions, 10×1-hour stress management sessions based on CBT vs ESM: 16 education sessions, 10×1-hour stress management sessions based on CBT and WL for 10-week period</td>
<td>CES-D, Bradburn Affect Balance Scale; STAI, SCL-90-R, MHLC, SIP, cognitive assessments</td>
<td>EXESM and WL groups showed reductions in depressive symptoms and SIP scores. EXESM showed improvements in anxiety and organized verbal processing. All groups increased mental efficiency performance.</td>
</tr>
</tbody>
</table>

(Continued)
Table 2 (Continued)

<table>
<thead>
<tr>
<th>Source</th>
<th>Study design</th>
<th>Sample size (n)</th>
<th>Comparison</th>
<th>Measurement instruments</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eiser et al [262]</td>
<td>Pilot study</td>
<td>I=10, C=8 with moderately severe, stable COPD, intervention group had significantly higher prevalence of anxiety than control group at baseline</td>
<td>Intervention: six 90 minutes sessions of CBT at weekly intervals vs controls: attended weekly for lung function and 6MWD for 6 weeks, but had no psychotherapy</td>
<td>HADS, 6MWD</td>
<td>Improvement in exercise tolerance in a group of ten anxious patients with severe COPD, without any change in anxiety scores</td>
</tr>
<tr>
<td>Coventry et al [263]</td>
<td>Review of 7 RCT studies</td>
<td>N=916 patients, most had moderate-to-severe COPD, with variable psychological morbidity</td>
<td>CBT intervention: 30–120 minutes x4–12 sessions group or individual face-to-face or remote</td>
<td>BDI, GDS, POMS-A, POMS-D, BAI, SCL-90</td>
<td>The meta-analysis revealed a small beneficial effect of CBT on both anxiety and depression, neither of which was statistically significant</td>
</tr>
<tr>
<td>Ramsenthaler et al [264]</td>
<td>Review of 13 RCT studies</td>
<td>COPD patients of all stages with mild-to-severe panic or anxiety symptoms</td>
<td>CBT intervention for the treatment of mild-to-severe anxiety and panic in adult patients with mild-to-severe COPD</td>
<td>Validated instruments of anxiety</td>
<td>7 of 13 studies reported a significant impact of CBT on anxiety. Six other studies, one of which was an adequately powered RCT, failed to show an improvement in anxiety. The meta-analyses showed a small effect of CBT on anxiety</td>
</tr>
<tr>
<td>Baraniak and Sheffield [265]</td>
<td>Review of 9 studies, 4 RCT</td>
<td>N=523 patients, most had moderate-to-severe COPD, with variable psychological morbidity</td>
<td>Individual or group CBT, CBT-based education, individual psychotherapy and muscle relaxation training, over a single 2-hour intervention to 12 weekly sessions vs control groups with education only, PR and exercise, weekly lab tests</td>
<td>Generic and disease-specific QoL and various psychological instruments</td>
<td>Improvement in anxiety scores was reported in 4 out of 9 studies. Four out of 7 studies reported a statistically significant improvement in depression scores. 5 studies considered QoL; findings were mixed and unclear</td>
</tr>
<tr>
<td>Coventry and Gellatly [72]</td>
<td>Review of RCTs and nonrandomized trials</td>
<td>3 RCTs (165 patients) and one nonrandomized controlled trial (n=8 patients), with stable and severe COPD and mild-to-moderate anxiety and depression</td>
<td>CBT alone or alongside exercise and/or education; comparators included WL control, standard care, exercise, education, and/or CBT</td>
<td>CES-D, BAI, BDI, HADS, STAI, and several measures of exercise, education, and stress management at 6, 10, and 12 weeks</td>
<td>There was limited evidence that CBT, when used with exercise and education, could contribute to significant reductions in anxiety and depression in patients with clinically stable and severe chronic obstructive pulmonary disease. Only one RCT (30 patients) reported a large statistically significant effect size in favor of CBT; this trial used CBT alongside education and exercise</td>
</tr>
</tbody>
</table>

**Abbreviations:** BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; BDII, Beck Depression Inventory 1996 revision; HADS, Hospital Anxiety and Depression Scale; HADS-D, Hospital Anxiety and Depression Scale – Depression subscale; STAI, Spielberger’s state–trait anxiety inventory; SSAl, Spielberger’s State Anxiety Inventory; CES-D, Center for Epidemiologic Studies Depression Scale; GDS, Geriatric Depression Scale; POMS-A, Profile of Mood States Anxiety Scale; POMS-D, Profile of Mood States Depression Scale; SIP, Sickness Impact Profile; ESM, education and stress management; EKSEM, exercise, education and stress management; CQ-SR, Self-Reported Chronic Respiratory Questionnaire; RCT, randomized controlled trial; WL, waiting list; C, control group; CBT-I, cognitive behavioral therapy for insomnia; G1, Group 1; G2, Group 2; G3, Group 3; COPD, chronic obstructive pulmonary disease; SCL-90-R, Hopkins Symptoms Checklist Revised; MHLC, Multidimensional Health Locus of Control inventory; 6MWD, 6-minute walk distance; FFRP, pulmonary rehabilitation program; SGRQ, St Georges Respiratory Questionnaire; CST, coping skills training; UMC, usual medical care; QoL, quality of life; FEV , forced expiratory volume in 1 second; FVC, forced vital capacity; MRC, Medical Research Council; HADS-A, Hospital Anxiety and Depression Scale – Anxiety subscale; CRQ-M, Chronic Respiratory Questionnaire; SCL-A, Anxiety subscale of the Symptom Checklist-90; WE, wellness education.
Table 3 Relaxation therapy and alternative treatments

<table>
<thead>
<tr>
<th>Source</th>
<th>Study design</th>
<th>Sample size (n)</th>
<th>Comparison</th>
<th>Measurement instruments</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mkacher et al</td>
<td>RCT</td>
<td>I=32, C=30 COPD patients entering PRP</td>
<td>6 months PRP with or without balance training 3 times a week</td>
<td>HADS, SGRQ, 6MWT</td>
<td>Anxiety decreased significantly in both groups with a greater change in the intervention group. Only the intervention group had an improved depression score at the end of 6 months. Both the intervention and PR-only group improved their QoL with a significant intergroup difference</td>
</tr>
<tr>
<td>Reychler et al</td>
<td>RCT</td>
<td>N=41 COPD patients entering PRP FEV₁: 38.6%±12.5%</td>
<td>One session of PRP with or without ambient music</td>
<td>HADS, Borg scales, dyspnea VAS</td>
<td>Perceived exertion was not modified by ambient music, but anxiety was improved</td>
</tr>
<tr>
<td>Kaymaz et al</td>
<td>Nonrandomized controlled observational study</td>
<td>I=23, C=27 Stage III COPD patients</td>
<td>C = PRP 3 days a week for 8 weeks vs I = NMES 2 days a week for 10 weeks</td>
<td>HADS, SGRQ, MRC, ISWT, ESWT, MMT</td>
<td>In the I group, significant improvements were observed in the HADS scores and in all SGRQ domains except symptom domain. NMES can be used as an effective treatment strategy in PR programs for peripheral muscle training in patients with severe COPD</td>
</tr>
<tr>
<td>Valenza et al</td>
<td>RCT</td>
<td>I=23, C=23, N=46 male patients hospitalized for COPD exacerbation</td>
<td>10-day controlled breathing intervention vs standard care</td>
<td>HADS, SGRQ, MMRC, EQ-5D</td>
<td>Controlled breathing exercises improve anxiety and depression in patients hospitalized for COPD exacerbation</td>
</tr>
<tr>
<td>Leung et al</td>
<td>RCT</td>
<td>N=42 COPD patients FEV₁: 59%±16%</td>
<td>TCG: short-form Sun-style t’ai chi twice weekly for 12 weeks vs CG: usual medical care</td>
<td>HADS, CRQ, ISWT, ESWT, MPPB, FPI</td>
<td>At study completion, the ESWT time was significantly longer in the TCG than the CG. the TCG had a significant improvement in ISWT, MPPB, FPI, CRQ HADS anxiety domain</td>
</tr>
<tr>
<td>Santana et al</td>
<td>Prospective observational study</td>
<td>N=25 pre–lung transplant patients, 5 with COPD</td>
<td>Two-phase, 12-week IYP that included 2 hours biweekly classes</td>
<td>HADS, CRQ, HUI, 6MST</td>
<td>Changes in HADS anxiety and CRQ fatigue scores were statistically significant and changes in HUI ambulation, pain, emotion, and overall score were clinically important</td>
</tr>
<tr>
<td>Lord et al</td>
<td>RCT</td>
<td>N=24 COPD patients I=13, FEV₁: 44.4%±14.4% C=11, FEV₁: 63.5%±25.5%</td>
<td>Singing classes twice weekly for 8 weeks vs a film club for 8 weeks, once weekly</td>
<td>HADS, SF-36, CAT</td>
<td>No significant differences between groups in the response of measures of breathing control, functional exercise capacity or daily physical activity. Similar improvements in the mental component score of the SF-36 in both groups. Significant difference between the response of the physical component score favoring the singing group</td>
</tr>
</tbody>
</table>

(Continued)
Table 3 (Continued)

<table>
<thead>
<tr>
<th>Source</th>
<th>Study design</th>
<th>Sample size (n)</th>
<th>Comparison</th>
<th>Measurement instruments</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yeh et al&lt;sup&gt;80&lt;/sup&gt;</td>
<td>RCT</td>
<td>I=5, C=5, N=10</td>
<td>moderate-to-severe COPD patients</td>
<td>CESD, CRQ, 6MW</td>
<td>Significant improvement in CRQ score among the tai chi participants, compared to the usual-care group. There were nonsignificant trends toward improvement in 6MW, CESD scores.</td>
</tr>
<tr>
<td>Lord et al&lt;sup&gt;82&lt;/sup&gt;</td>
<td>RCT</td>
<td>I=15, C=13, N=28</td>
<td>COPD patients FEV&lt;sub&gt;1&lt;/sub&gt;: 37.2%±18.6%</td>
<td>HADS, SF-36, SGRQ, ISWT</td>
<td>The physical component score of the SF36 improved in the singers compared to the controls. Singers also had a significant fall in HAD anxiety score.</td>
</tr>
<tr>
<td>Donesky-Cuenco et al&lt;sup&gt;81&lt;/sup&gt;</td>
<td>RCT</td>
<td>N=29 stable COPD patients FEV&lt;sub&gt;1&lt;/sub&gt;: 47.7%±15.6%</td>
<td>Twice-weekly 12-week yoga program vs usual care</td>
<td>CESD, SSAI, PF1, SF-36, CRQ, 6MW</td>
<td>After the program, the subjects tolerated more activity with less dyspnea-related distress and improved their functional performance. No significant intergroup difference on CESD, SSAI scores.</td>
</tr>
<tr>
<td>Singh et al&lt;sup&gt;71&lt;/sup&gt;</td>
<td>RCT</td>
<td>N=72 COPD patients hospitalized for COPD exacerbation</td>
<td>Music vs PMR. Music group listened to a self-selected music of 60–80 beats per minute for 30 minutes. PMR group practiced relaxation through a prerecorded audio of instructions of 16 muscle groups</td>
<td>SSAI, STAI, physiologic measures</td>
<td>Music and PMR are effective in reducing anxiety and dyspnea along with physiologic measures in two sessions in COPD patients hospitalized with exacerbation. However, reductions in the music group were greater compared to the PMR group.</td>
</tr>
<tr>
<td>Lolak et al&lt;sup&gt;79&lt;/sup&gt;</td>
<td>RCT</td>
<td>N=83 COPD patients entering PRP</td>
<td>8-week PR program 2 days per week with or without PMR – 25 min/wk during weeks 2–8</td>
<td>HADS</td>
<td>The results favored the PMR group but did not reach statistical significance. Adding structured PMR training to a well-established PR program may not confer additional benefit in the further reduction of anxiety and depression in patients receiving PR. Subjects who used DAS while walking had improved functional performance and decreased perceptions of dyspnea, whereas control subjects could not maintain post-PRP gains. No significant differences were noted for the remaining variables.</td>
</tr>
<tr>
<td>Bauldoff et al&lt;sup&gt;72&lt;/sup&gt;</td>
<td>Experimental, randomized, two-group design</td>
<td>I=12, C=12, N=24</td>
<td>moderate-to-severe COPD patients following completion of a PRP</td>
<td>HADS, ADL, 6MW, QoL</td>
<td>A treatment program of dyspnea management strategies, PRP components, is not sufficient to produce significant improvement in dyspnea, exercise tolerance, health-related quality of well-being, anxiety, or depression.</td>
</tr>
</tbody>
</table>
Strategies to improve anxiety and depression in patients with COPD

Gift et al\(^{(1)}\)

RCT

N=26 COPD patients stage II

4 weeks: 4 sessions, 20 minutes PMR with prerecorded tapes vs sit quietly for 20 minutes

STAI, physiologic measures

Dyspnea, anxiety, and airway obstruction were reduced in the relaxation group while the control group remained the same or became worse

Volpato et al\(^{(1)}\)

Meta-analysis: 25 RCTs

I=615, C=627, N=1,426 COPD patients stage I–III

1) Relaxation techniques; 2) PMR; 3) guided imagery; 4) distraction therapy; 5) biofeedback; 6) breathing techniques; 7) yoga; 8) Tai Chi; 9) acupressure vs control group

Validated instruments of anxiety, depression, QoL, and physiologic measures

Relaxation techniques showed minor positive effect on the value of the percentage of predicted FEV\(_1\), as well as a slight effect on levels of both the anxiety and depression. The higher effect size was found in the QoL value

Abbreviations: HADS, Hospital Anxiety and Depression Scale; MRC, Medical Research Council; iSwT, incremental shuttle walking test; ESWT, endurance shuttle walking test; SGRQ, St Georges Respiratory Questionnaire; MMT, manual muscle testing; MMRC, Modified Medical Research Council Scale; EQ-5D, European Quality of Life Questionnaire; VAS, visual analog scale; STAI, Spielberger state–trait anxiety inventory; SSAI, Spielberger's state anxiety inventory; CESD, Center for Epidemiologic Studies’ Depression; QWB, quality of well-being scale; ADL, activities of daily living; 6Mw, 6-minute walk distance; HUi, Health Utilities index; 6MST, 6 minute walk test; SF-36, Medical Outcomes Study Short-Form 36; FPI, Functional Performance Inventory; CAT, COPD assessment test score; MPPB, modified physical performance battery test; I, intervention group; C, control group; PMR, progressive muscle relaxation; QoL, quality of life; TCG, t'ai chi group; CG, control group; DAS, distinctive auditory stimuli; CRQ, Chronic Respiratory Questionnaire; fYP, iyengar yoga program; NMES, neuromuscular electrical stimulation; 6MWT, 6-minutes walking test.

### Table 4 Comprehensive PR in COPD patients

<table>
<thead>
<tr>
<th>Source</th>
<th>Study design</th>
<th>Sample size (n)</th>
<th>Intervention</th>
<th>Measurement instruments</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luk et al(^{(1)})</td>
<td>Prospective cohort study</td>
<td>n=83 patients with COPD who had completed PR, FEV(_1) mean: 46%</td>
<td>Assessment after 22 months following an 8-week PRP</td>
<td>HADS, CRQ, iSwT</td>
<td>ISWT gain was lost at the long-term reassessment. In CRQ, only the domains of dyspnea and fatigue remained statistically significant, and improvements in HADS scores persisted at the long-term reassessment but were not statistically significant</td>
</tr>
<tr>
<td>Sciiriha et al(^{(1)})</td>
<td>Prospective observational study</td>
<td>n=60 COPD patients stage I–IV with MRC grade 2 or above</td>
<td>PRP for 12 weeks 2 hours sessions, twice-weekly</td>
<td>HADS, SGRQ, 6MWT, Borg scale, CAT</td>
<td>Anxiety scoring decreased significantly by 12 weeks, while the depression rating improved by 8 weeks. No significant changes on anxiety ratings for stage III–IV COPD participants as opposed to the milder group of patients who had significant changes after 3 weeks. Participants with an MRC 2–3 had significant changes in depression ratings after 12 weeks of PRP</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Source</th>
<th>Study design</th>
<th>Sample size (n)</th>
<th>Intervention</th>
<th>Measurement instruments</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grosbois et al</td>
<td>Retrospective</td>
<td>n=211 patients</td>
<td>Home-based PR individually managed once a week for 8 weeks unsupervised on the</td>
<td>HADS, 6MST, VSRQ</td>
<td>6MST was significantly improved after completion of the program, at 6 and</td>
</tr>
<tr>
<td></td>
<td>observational study</td>
<td>with COPD</td>
<td>other days of the week</td>
<td></td>
<td>12 months. HADS and VSRQ scores improved after PR, and this improvement</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FEV$_{1}$ mean:</td>
<td>once supervised on unsupervised on the other days of the week unsupervised on</td>
<td></td>
<td>persisted at 6 and 12 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td>41.5%±17.7%</td>
<td>the other days of the week unsupervised on the other days of the week unsupervised on</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boutou et al</td>
<td>Prospective</td>
<td>n=787 COPD</td>
<td>Home-based PR individually managed once a week for 8 weeks unsupervised on the</td>
<td>HAD-A, HAD-D, CRDQ, CAT,</td>
<td>Significant improvements in 6MWT or ISWT distance. Anxiety and depression</td>
</tr>
<tr>
<td></td>
<td>observational study</td>
<td>outpatients</td>
<td>other days of the week</td>
<td>6MWT, ISWT</td>
<td>scores fell post PR. QoL also improved with significant fall in CAT scores while CRDQ scores increased. Patients who completed PR were significantly older with less severe airflow obstruction, lower anxiety and depression scores, less dyspnea and better HRQoL</td>
</tr>
<tr>
<td>da Costa et al</td>
<td>Prospective</td>
<td>n=125 COPD</td>
<td>Home-based PR of 3 weekly sessions of 60 minutes duration for 12 weeks, a total of</td>
<td>BAI, BDL, SGRQ</td>
<td>Significant decreases in anxiety and depression scores and improvements in QoL were observed. Weak correlations were observed when correlating the BAI to the SGRQ</td>
</tr>
<tr>
<td></td>
<td>observational study</td>
<td>patients</td>
<td>36 sessions</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>FEV$_{1}$ mean:</td>
<td>PRP of 3 weekly sessions of 60 minutes duration for 12 weeks, a total of 36 sessions</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>43.18%±18.79%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jácome and Marque</td>
<td>Quasiexperimental</td>
<td>n=26 COPD</td>
<td>Home-based PR of 3 weekly sessions of 60 minutes duration for 12 weeks, a total of</td>
<td>DASS, SGRQ, 6MWT, MMRC,</td>
<td>Significant improvements were observed on 6MWT, MMRC, TUG and SGRQ total scores. No significant improvement in the SGRQ impact score and DASS scores</td>
</tr>
<tr>
<td></td>
<td>study</td>
<td>patients</td>
<td>36 sessions</td>
<td>TUG</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>FEV$_{1}$ mean:</td>
<td>12-week PR program</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>84.8%±6.4%</td>
<td>3 sessions/week, 60 minutes each, with exercise training and psychoeducation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tselebis et al</td>
<td>Prospective</td>
<td>n=101 stage I–IV COPD patients</td>
<td>Home-based PR for a period of 3 months, with three sessions per week, each lasting 50 minutes</td>
<td>STAI, BDI</td>
<td>Significant decreases in anxiety and depression rates were observed. A statistically significant reduction in anxiety and depression was revealed at all stages of COPD</td>
</tr>
<tr>
<td></td>
<td>observational study</td>
<td>patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bhandari et al</td>
<td>Retrospective</td>
<td>n=366 COPD</td>
<td>Sixteen 3-hour sessions given twice weekly over an 8-week outpatient PR program</td>
<td>HADS, CRQ-SR, 6MST</td>
<td>Of the 366 patients, 257 completed the program and 235 completed final outcome evaluation. Among patients who completed PR, there were significant improvements on all dimensions (CRQ-SR, 6MST scores, and reduced HADS scores)</td>
</tr>
<tr>
<td></td>
<td>observational study</td>
<td>patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>FEV$_{1}$ mean:</td>
<td>Sixteen 3-hour sessions given twice weekly over an 8-week outpatient PR program</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>47%±17% at program entry, 25% had abnormal anxiety scores and 17% had abnormal depression scores</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hogg et al</td>
<td>Prospective</td>
<td>n=812 stage I–IV COPD patients were assessed</td>
<td>656 started PR twice or once weekly for 8 weeks</td>
<td>HADS, ISWT, CRQ, MRC</td>
<td>441 completed. Significant improvements were seen in ISWT, CRQ-SR and HADS scores. Twice-weekly compared with once-weekly programs showed similar improvement</td>
</tr>
<tr>
<td></td>
<td>observational study</td>
<td>patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Author et al.</td>
<td>Study Type</td>
<td>COPD patients assessed</td>
<td>6-week outpatient PRP, including education, psychosocial support and training sessions</td>
<td>HADS, COPD self-efficacy scale, ISWT</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
<td>------------------------</td>
<td>-----------------------------------------------------------------</td>
<td>----------------------------------</td>
<td></td>
</tr>
<tr>
<td>Bentsen et al.</td>
<td>Prospective observational study</td>
<td>COPD patients assessed at baseline (T1: N=100), immediately before (T2: N=66), immediately after (T3: N=54) and 3 months after (T4: N=43)</td>
<td>A tendency of less anxiety and depression immediately after (T3) compared with immediately before (T2) the PR program, but the changes were not significant. Higher level of self-efficacy and better exercise capacity are suggested to relieve anxiety and depression</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harrison et al.</td>
<td>Comparative effectiveness research</td>
<td>n=18 patients with COPD</td>
<td>PRP twice a week for 7 weeks. A “responder” was defined as achieving a change of ≥48 m on ISWT and a “completer” if attended discharge assessment for PR</td>
<td>HADS, ISWT, CRQ-SR</td>
<td></td>
</tr>
<tr>
<td>Bratås et al.</td>
<td>Prospective cohort study</td>
<td>n=111 stage I–IV COPD patients measured at baseline, 4 weeks and 6-month follow up</td>
<td>Evaluate the short- and long-term effects of a 4-week inpatient PRP</td>
<td>HADS, SGRQ</td>
<td></td>
</tr>
<tr>
<td>Von Leupoldt et al.</td>
<td>Prospective observational study</td>
<td>n=238 COPD patients with mean FEV1 % predicted =54</td>
<td>3-week outpatient PR program was performed 6 h/d for 5 d/wk</td>
<td>6MWD, 6MWT, HADS, SF-36</td>
<td></td>
</tr>
<tr>
<td>Pirraglia et al.</td>
<td>Prospective observational study</td>
<td>n=81 COPD patients with mean FEV1, 1.23±0.39 L</td>
<td>PRP twice weekly for 8 weeks</td>
<td>BDI, BAL, CRQ-SR</td>
<td></td>
</tr>
<tr>
<td>Bratås et al.</td>
<td>Prospective observational study</td>
<td>n=136 patients with mild-to-severe COPD</td>
<td>Inpatient PR for 7.5 hours a day, 5 d/wk for 4 weeks</td>
<td>HADS, SGRQ, 6MWD, TDI</td>
<td></td>
</tr>
</tbody>
</table>

A PRP was significantly associated with improvements in 6MWD, dyspnea after the 6MWT and during activities, and increased physical and mental QoL, as well as reduced anxiety and depression. The CRQ-SR and BDI scores improved significantly. Improvement in depressive symptoms was associated with improvement in fatigue, emotion and mastery.

A PRP improves HRQL and exercise capacity and reduces depression in COPD patients. Patients with mild or moderate disease are more likely to achieve an improved HRQoL after rehabilitation than patients with severe or very severe disease.
<table>
<thead>
<tr>
<th>Source</th>
<th>Study design</th>
<th>Sample size (n)</th>
<th>Intervention</th>
<th>Measurement instruments</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spencer et al</td>
<td>RCT</td>
<td>n=59 patients</td>
<td>Supervised, outpatient-based exercise plus unsupervised home exercise vs</td>
<td>HADS, 6MWD, SGRQ</td>
<td>12 months following pulmonary rehabilitation both weekly, supervised, outpatient-based exercise plus unsupervised home exercise and standard care of unsupervised home exercise successfully maintained 6MWD, SGRQ scores in subjects with moderate COPD. No significant change from baseline to 12 months for HADS scores.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>with moderate</td>
<td>standard care of unsupervised home exercise training following an 8-week</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>COPD completed</td>
<td>PRP</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>an 8-week PRP</td>
<td>I=31, C=28</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ozdemir et al</td>
<td>RCT</td>
<td>n=50 male patients with COPD stage II and III</td>
<td>4-week water-based PRP for 35 minutes, three times a week (totally 12 sessions) vs only medical therapy</td>
<td>HADS, 6MWD, CRDQ</td>
<td>Water-based exercises are effective in improving QoL and anxiety level in COPD patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td>I=25, C=25</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Godoy et al</td>
<td>Prospective observational study</td>
<td>n=30 patients with severe and extremely severe COPD</td>
<td>12-week PRP, which included 24 physical exercise sessions, 24 respiratory rehabilitation sessions, 12 psychotherapy sessions and 3 educational sessions</td>
<td>BAI, BDI, SGRQ, 6MWI</td>
<td>Pre-PRP and post-PRP values revealed a significant decrease in the levels of anxiety and depression, as well as significant improvements in the distance covered on the 6MWI and the QoL index. The benefits provided by the PRP persisted throughout the 24-month study period.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elçi et al</td>
<td>RTC</td>
<td>n=78 inpatients</td>
<td>PRP (24 sessions, 90 minutes duration) vs standard medical care</td>
<td>HADS, SF-36, SGRQ, 6MWD</td>
<td>Significant differences were observed in the 6MWI measurements at the third month, as well as in the SF-36 QoL scale, SGRQ and HADS measurements at the second and third months, irrespective of FEV1. After PR, there was a significant improvement in the severity of depression, a decrease in symptoms, an increase in daily living activities, and a decrease in the total score of the SGRQ. Dyspnea measured by the MRC scale was significantly better in the PR group. PR may decrease psychosocial morbidity in COPD patients even when no specific psychological intervention is performed. Findings from this study also confirm the positive impact of PR on functional exercise capacity and HRQoL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>with severe COPD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paz-Díaz et al</td>
<td>RCT</td>
<td>n=24 patients</td>
<td>8-week PR program, 3 times a week for 8 weeks</td>
<td>BDI, STAI, MMRC, SGRQ</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>with severe COPD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>I=10, C=14</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Güell et al</td>
<td>RCT</td>
<td>n=40 patients</td>
<td>16 weeks of PR that included breathing retraining and exercise</td>
<td>MBHI, SCL-90-R, 6MWD,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>with severe COPD</td>
<td></td>
<td>CRQ</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>FEV1, 35±13%, I=18, C=17</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Strategies to improve anxiety and depression in patients with COPD

<table>
<thead>
<tr>
<th>Authors</th>
<th>Study Design</th>
<th>Participants</th>
<th>Intervention</th>
<th>Outcome Measures</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexopoulos et al</td>
<td>Prospective observational study</td>
<td>n=63 patients with COPD and major depression recruited from a pulmonary rehabilitation unit</td>
<td>Brief inpatient PRP (median length of stay was 16 days)</td>
<td>Hamilton Depression Scale</td>
<td>Approximately 51% of subjects met criteria for response and 39% met criteria for remission. History of treatment for depression was associated with limited change in depressive symptoms, whereas social support and satisfaction with treatment were predictors of improvement. Improvement of depression may be the result of behavioral interventions rather than the use of antidepressant drugs.</td>
</tr>
<tr>
<td>Kayahan et al</td>
<td>RCT</td>
<td>I=26 PR, C=19 Stage I–III COPD patients</td>
<td>2 months PR program, for 3 days and 2 1/2 hours weekly</td>
<td>HAM-A, HAM-D</td>
<td>There was a significant decrease in HAM-A scores in the rehabilitation group. On the contrary the HAM-A scores did not change in control group. The decrease in HAM-A scores in rehabilitation group was also statistically significant compared with the control group. There was no significant difference in HAM-D scores within the two groups and also there was no significant difference between the two groups in HAM-D scores. The health status, exercise tolerance and dyspnea intensity improved significantly in the rehabilitation group compared to the control group.</td>
</tr>
<tr>
<td>Arnardóttir et al</td>
<td>RCT</td>
<td>n=60 patients with COPD stage II and III</td>
<td>PR program twice weekly (90-minute duration) for 16 weeks after randomization to interval – 3-minute intervals (I) – or continuous training (C)</td>
<td>HADS, SF-36, CRDQ, 12 MWD</td>
<td>Interval training and continuous training were equally potent in improving peak exercise capacity, functional exercise capacity, dyspnea, mental health and HRQoL in patients with moderate or severe COPD.</td>
</tr>
<tr>
<td>Goldberg et al</td>
<td>Prospective observational study</td>
<td>n=45 patients with COPD stage III</td>
<td>3 weeks of inpatient PRP</td>
<td>BDI, Hamilton Anxiety Scale, Goldberg Scale, and Modified Borg Scale</td>
<td>The program significantly reduced anxiety and depression, and increased positive psychological outlook in severe pulmonary disease. Perceived breathlessness on the Borg Scale was significantly reduced. The effects of rehabilitation are not affected by baseline psychosocial factors. Patients with less favorable psychologic or sociodemographic conditions can also benefit from pulmonary rehabilitation.</td>
</tr>
<tr>
<td>Trappenburg et al</td>
<td>Prospective observational study</td>
<td>n=81 patients with COPD stage II–IV, FEV1: 40%±16%</td>
<td>3 months PR program (2 hours sessions, 3 times per week)</td>
<td>HADS, CRDQ, PFSDQ-M, 6MWT</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Source</th>
<th>Study design</th>
<th>Sample size (n)</th>
<th>Intervention</th>
<th>Measurement instruments</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Garuti et al[195]</td>
<td>Prospective</td>
<td>n=49 COPD patients, stage II–III, after an exacerbation</td>
<td>Inpatient PR program: twelve 3-hours daily sessions</td>
<td>HADS, SGRQ, 6MWD</td>
<td>Inpatient pulmonary rehabilitation may improve levels of anxiety and depression as well as symptoms, exercise capacity and HRQoL in moderate-to-severe COPD patients after an acute exacerbation. Inpatient pulmonary rehabilitation may improve levels of anxiety and depression as well as symptoms, exercise capacity and HRQoL in moderate-to-severe COPD patients after an acute exacerbation.</td>
</tr>
<tr>
<td>Cilione et al[196]</td>
<td>Prospective</td>
<td>n=132 COPD patients stage II and III recovering from an acute exacerbation</td>
<td>Inpatient PR program: 12 sessions (6 d/wk), lasted for 3 hours daily</td>
<td>HADS, SGRQ, 6MWD</td>
<td>6MWD increased by 34%, HAD-anxiety decreased by 16%, HAD-depression decreased by 13% and SGRQ decreased by 11% At 3 months both groups reported reduced anxiety on the Hospital Anxiety and Depression Scale and dimensions of QoL, but differences between groups were not significant. Shuttle walking distance increased significantly in the intervention group compared to controls.</td>
</tr>
<tr>
<td>White et al[197]</td>
<td>RCT</td>
<td>n=103 COPD patients stage III, n₁=44, n₂=49</td>
<td>n₁: PRP twice a week for 2-hour session for 6 weeks vs n₂: brief advice</td>
<td>HADS, SF-36, CRQ, shuttle walking distance</td>
<td>PR produced statistically significant falls in mean HADS scores, which remained significantly lowered at 6-month follow up. Patients with high anxiety levels showed significantly greater improvements in shuttle walking distance than those with low HAD scores.</td>
</tr>
<tr>
<td>Withers et al[198]</td>
<td>Prospective</td>
<td>n=99 COPD patients stage III (35 had significant anxiety at screening and 18 significant depression)</td>
<td>3 months PR program</td>
<td>HADS, shuttle walk distance</td>
<td>Intervention participants in the PRP group, compared to the other 2 groups, reported improved endurance, reduced anxiety, and improved cognitive performance.</td>
</tr>
<tr>
<td>Emery et al[199]</td>
<td>RTC</td>
<td>n=79 COPD outpatients stage II–III, EXESM =29, ESM =25, W =25</td>
<td>EXESM: 10-week PR with exercise, education, and stress management ESM: education and stress management; and W: wait list control</td>
<td>CES-D, SCL-90-R, STAI, SIP and Physiologic Measures</td>
<td>Intervention participants in the PRP group, compared to the other 2 groups, reported improved endurance, reduced anxiety, and improved cognitive performance.</td>
</tr>
<tr>
<td>Ries et al[200]</td>
<td>RTC</td>
<td>n=119 stable COPD outpatients stage 1–III, n₁=57, n₂=62</td>
<td>n₁: 8-week PR program (twelve 4-hour sessions) vs n₂: an 8-week education program (four 2-hour sessions biweekly for 8 weeks)</td>
<td>CES-D, Quality of Well-Being Scale and Physiologic Measures</td>
<td>Measures of lung function, depression, and general QoL did not differ between groups. Differences tended to diminish after 1 year of follow-up.</td>
</tr>
<tr>
<td>Emery et al[201]</td>
<td>Prospective</td>
<td>64 PR patients with COPD FEV₁/FVC &lt;0.7</td>
<td>PRP for 4 hours a day, 5 d/wk for 30 days</td>
<td>SCL-90-R, PGWI, neuropsychological assessment</td>
<td>Enhanced cognitive functioning and psychological well-being.</td>
</tr>
<tr>
<td>Abbreviations: HADS, Hospital Anxiety and Depression Scale; ISWT, incremental shuttle walk test; HAM-D, Hamilton Depression Rating Scale; HAM-A, Hamilton Anxiety Rating Scale; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; STAI, State Trait Anxiety Inventory; MMRC, Modified Medical Research Council Scale; CRQ-SR, Chronic Respiratory Questionnaire – Self reported; CRDQ, Chronic Obstructive Disease Questionnaire; SCL-90-R, Hopkins Symptoms Checklist Revised; DASS, Depression Anxiety and Stress Scales; CeS-D, Center for Epidemiologic Studies Depression Scale; PGwi, Psychological General well-being index; QoL, quality of life; SF-36, 36-item Short Form Health Survey; 6MWT, 6-minutes walking test; MBHI, Millon Behavior Health Inventory; 12 MWD, 12 minutes walking distance; SGRQ, St Georges Respiratory Questionnaire; SIP, Sickness Impact Profile; TDI, Transitional Dyspnea Index; MHLC, Multidimensional Health Locus of Control inventory; 6MST, 6-minute stepper test; TUG, Timed Up and Go; VSRQ, Visual Simplified Respiratory Questionnaire; MCID, minimal clinically important difference; PFSDQ-M, Modified Pulmonary Functional Status and Dyspnea Questionnaire; MRC, Medical Research Council; ADL, Activities-in-Daily-Life; DPI, Dutch Personality Inventory; PR, pulmonary rehabilitation; TF-IMT, target-flow inspiratory muscle training; I, intervention group; C, control group; FEV\textsubscript{1}, forced expiratory volume in 1 second; FVC, forced vital capacity; HRQoL, health-related QoL; CAT, COPD assessment test; HAD-D, Hospital Anxiety and Depression Scale – Depression subscale; HAD-A, Hospital Anxiety and Depression Scale – Anxiety subscale.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
retardation and necessitates support networks and protection against continuous vascular damage. Late-onset depression has been found to be more refractory to treatment with antidepressants,\textsuperscript{124,125} associated with a greater degree of patient apathy,\textsuperscript{126} and less often associated with a family history of depression.\textsuperscript{127,128} On the other hand, early-onset depression is defined as depression that develops prior to the diagnosis of COPD, often during an individual’s youth. This type of depression is often reflective of a genetic vulnerability to depression, which increases adolescents’ risk for developing addiction to nicotine and presents with more classic symptoms, but might have greater difficulty with smoking cessation.\textsuperscript{129,130}

It is also necessary to consider that the prescribed medications should not cause sedation or respiratory depression in patients with chronic respiratory conditions. Plus, the ideal medication should have a low side effect profile, a short half-life with no active metabolites,\textsuperscript{3} and provoke few drug interactions, especially when considering the other already administered medications for COPD.\textsuperscript{131} The most commonly used agents in COPD are $\beta_2$-adrenergic agonists and anticholinergic medication. $\beta_2$-adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Thus coadministration with some SSRIs and TCAs that can prolong QT interval may result in additive effects and increased risk of ventricular arrhythmias. Also, the anticholinergic action of TCAs may be added to that of anticholinergic bronchodilators used in COPD. Besides pharmacodynamics, pharmacokinetic interactions should be considered, and hence medications with the lowest potential to interfere with cytochrome P450 system should be considered.\textsuperscript{132}

In general, antidepressants seem to have little effect on ventilator drive, but caution should be taken while prescribing certain antidepressants (TCAs and mirtazapine) in COPD patients with hypercapnia.\textsuperscript{112,133} On the contrary, benzodiazepines may cause respiratory depression and should be avoided, especially for patients with COPD who are CO\textsubscript{2} retainers.\textsuperscript{134,135} A recent prospective study\textsuperscript{136} evaluating the safety of benzodiazepines and opioids in patients with very severe COPD indicated that concurrent use of benzodiazepines and opioids in lower doses (<0.3 defined daily doses per day) was not associated with increased admissions or mortality, whereas higher doses (>0.3 defined daily doses per day) might increase mortality. Additionally, $\beta$-blockers are contraindicated in these patients, despite their anxiolytic effect due to their potential risk of bronchoconstriction.\textsuperscript{73}

Low-potency atypical antipsychotics in very small dosages may alleviate anxiety symptoms in these patients, but should be used with caution as they can have potential neurological and cardiovascular side effects.\textsuperscript{26}

Small, placebo-controlled trials of antidepressant drug therapy in patients with COPD did not demonstrate significant treatment effects, with the exception of one study, in 1992,\textsuperscript{137} which indicated high efficacy for nortriptyline in improving short-term outcomes for depression, anxiety, cognitive function, and overall disability. Other TCAs have been tested, such as doxepine,\textsuperscript{138} imipramine, and amitriptyline,\textsuperscript{139,142} with contradictory results. More recent studies\textsuperscript{143,147} have used SSRIs, the current first-line medications for the management of depression, but most suffered from methodological flaws. In few randomized, double-blind, placebo-controlled studies, sertraline,\textsuperscript{145,146} fluoxetine,\textsuperscript{143,148} citalopram,\textsuperscript{149} and paroxetine\textsuperscript{147} offered improvements in quality of life, dyspnea, and fatigue. Start-up side effects with SSRIs include gastrointestinal upset, headache, tremor, and either psychomotor activation or sedation, which is frequently problematic in COPD patients. Treatment timelines necessitate checking the tolerance of medication during 1–3 weeks, then evaluating the response during 2–4 weeks, and if there is response, it is important to complete symptom resolution and move on to continuation and then maintenance phase. In case there is none or inadequate response, augmenting strategies are advised or change of medication is required.\textsuperscript{14} Either way, it is necessary to consult a psychiatrist\textsuperscript{146} in cases of suicidal or self-injurious behavior, psychotic or bipolar depression, or other psychiatric comorbidities (eg, substance abuse, personality disorders). The presence of complex psychological issues, multimorbidity, frailty, and polypharmacy also necessitates integrated and comprehensive approach for the care of these people.\textsuperscript{151}

Concerning anxiety, several studies have investigated the effectiveness of specific medications\textsuperscript{152} with contradictory results for buspirone\textsuperscript{153,154} and inconclusive results for SSRIs, even though they are better tolerated and can relieve symptoms of panic.\textsuperscript{145,146} But compliance may be poor.\textsuperscript{143} A recent Cochrane review\textsuperscript{155} on pharmacological interventions for the treatment of anxiety in COPD patients analyzed four studies and found insufficient evidence of benefit for any of medications included. Two studies using SSRIs showed a nonsignificant reduction in anxiety symptoms,\textsuperscript{144,156} while two other studies using TCA and azapirones did not show any improvement.\textsuperscript{138,154} Anticonvulsants such as gabapentin have also been prescribed for the treatment of anxiety symptoms in COPD patients.\textsuperscript{73}

Some authors report\textsuperscript{143,157} that patients with COPD and psychiatric comorbidity are reluctant to take yet another
medication, possibly because of stigma associated with the disease or denial, and as mentioned before, data supporting the efficacy of medication-only treatment are extremely limited.158,159

When implementing treatment strategies for COPD patients, it is important to remember that there is a greater possibility for medical comorbidities, increased risk for medication interactions, and greater physical debilitation than the community population.160 An overview of studies on pharmacological treatment for anxiety and depression in COPD patients is summarized in Table 1.

**Psychotherapeutic interventions**

Patients prefer nondrug treatments,161 and clinical guidelines117,162 promote nonpharmacological interventions as first-line therapy for depression and anxiety in people with long-term conditions. NICE recommends use of low- (eg, self-help programs) or high-intensity (individual or group CBT) psychosocial interventions depending on the severity of mood symptoms.163 Both individual and group therapy psychological interventions are useful in promoting more adaptive coping in COPD patients.92

**CBT**

Evidence suggests that individualized or group CBT is the treatment of choice for addressing the maladaptive coping in the COPD patient with mental health difficulties, because of the time-limited and action-oriented nature of the intervention.164 According to this psychotherapeutic approach, emphasis is given to the effect of cognitions on mood and behavior. This model of psychotherapy assumes that maladaptive, or faulty, thinking patterns cause maladaptive behavior and “negative” emotions. Maladaptive behavior is behavior that is counterproductive or interferes with everyday living.14 The treatment focuses on changing an individual’s thoughts (cognitive patterns) in order to change his or her behavior and emotional state. Therapists attempt to make their patients aware of these distorted thinking patterns, or cognitive distortions, that fuel anxiety and depressive symptoms and change them (a process termed cognitive restructuring).14 Therapy focuses on helping patients discover alternative solutions and promote more adaptive coping styles in order to overcome adversities and effectuate operational techniques to address their problems.165–167

Mental health guidelines recommend CBT as the treatment of choice for a range of mood and anxiety disorders and as an adjunct to other treatments. Low-intensity CBT-based psychosocial interventions are recommended for people with mild-to-moderate anxiety and/or depression, whereas high-intensity psychological interventions using CBT in combination with medication is recommended for people with moderate-to-severe depression.162,163 Not all aspects of CBT may be necessary to produce a therapeutic effect. Purely behavioral interventions can be as effective as CBT for patients with depression.168

Some studies report that there is potential for psychological interventions to reduce anxiety and depression in people with COPD.169,170 A recent meta-analysis of four CBT studies for anxiety and depression in COPD patients indicated improvements in these symptoms.171 Also, based on randomized controlled trials, CBT resulted in improvement in symptoms of anxiety and depression (Table 2), especially when used with exercise and education.172

**Group psychotherapy**

Group psychotherapy is a financially attractive approach in response to the realities of limited resources, regardless of its theoretical orientation, because it involves fewer therapists, less therapist per person-hours, and serves more patients.

The group context and group process, if explicitly utilized within the principles of system dynamics, offers valuable healing opportunities.14 Therapeutic principles173,174 termed “therapeutic” factors, include the experience of relief from emotional distress through the free and uninhibited expression of emotion, feeling a sense of belonging, acceptance, and validation. Within a context that reflects the individual’s perception of reality, group members share experiences and feelings and develop social skills through a modeling process.

The therapist’s interventions facilitate group activities by taking advantage of the inherent assets of the team, ensuring that it runs efficiently with appropriate boundaries being maintained.14

**Relaxation therapy and alternative treatments**

Relaxation therapy encompasses a range of techniques such as breathing exercises, sequential muscle relaxation, biofeedback, guided imagery, distraction therapy, hypnosis, meditation/mindfulness, and physical posture therapy.175,176 Often, some of these techniques are components of PR or are used as an adjunct to other therapies (eg, CBT).122 The purpose of this therapy is to promote psychological change by effectively managing physiological changes accompanying anxiety. In other words, regulation of the sympathetic nervous system and management of the stimulation of certain regions
of the hypothalamus facilitate the relaxation response.\textsuperscript{177} In this perspective, relaxation techniques are often used to inhibit anxiety, increasing the patient’s perception of self-control or modulating his or her emotions, in order to promote the perceived well-being of the subject.

A meta-analysis of trials with relaxation-based therapies for COPD patients indicated statistically significant beneficial effects on both dyspnea and psychological well-being.\textsuperscript{178} Another recent meta-analysis on the effects of relaxation techniques, of 25 randomized controlled trials including both inpatients and outpatients with COPD, showed a minor positive effect on respiratory function as well as a slight effect on levels of both the anxiety and depression. The higher effect size was found in the quality of life value.\textsuperscript{176}

Several other studies have investigated other types of relaxation approaches.\textsuperscript{179} In a pilot study, the authors argued that the introduction of Tai Chi exercises was worth exploring in patients with COPD,\textsuperscript{180} while in another study,\textsuperscript{181} yoga exercises were performed. Singing lessons have also been used as an intervention in patients with COPD.\textsuperscript{182,183} The basic theory is that singing lessons could improve quality of life or functional status in these patients.\textsuperscript{184} Regarding these less traditional interventions, there is still lack of certainty about their applicability, their long-term effectiveness, the active component (physical or psychological), and how they can be incorporated into standard care.\textsuperscript{185} An overview of studies on relaxation therapies and alternative treatments for anxiety and depression in COPD patients is summarized in Table 3.

**PR**

Treatment strategies include PR, because it improves patient’s ability to participate in stress-reducing activities and increases their sense of self mastery. It also improves quality of life by increasing patients’ perception of available social supports.\textsuperscript{186} According to the American Thoracic Society and the European Respiratory Society, PR\textsuperscript{187} is an evidence-based multidisciplinary and comprehensive intervention for patients with chronic respiratory diseases who are symptomatic and often have decreased daily life activities.

The ideal patient for PR is one with functional limitations, moderate-to-severe lung disease, who is stable on standard therapy, without comorbid serious or unstable medical conditions, willing to learn about the disease, and motivated to devote time and effort necessary to benefit from a comprehensive care program.\textsuperscript{188}

The interdisciplinary team of health-care professionals in PR may include physicians, nurses, respiratory and physical therapists, psychologists, and exercise specialists.\textsuperscript{151} PR programs operate by means of progressive exercise, training of respiratory function, and psychoeducation, so that patients obtain better exercise tolerance with less dyspnea. The goal is to restore the patient to the highest possible level of independent function.\textsuperscript{189} Patients are educated about their disease and learn breathing techniques to reduce air hunger and exercises to optimize oxygen use, and this in turn improves exercise tolerance. Key outcomes such as exercise capacity and overall health-related quality of life may be accurately measured.\textsuperscript{190–192}

Exercise-based PR programs have been the most consistently helpful interventions for minor mood symptoms in COPD patients,\textsuperscript{193–195} but the greatest improvements in anxiety and depression are usually in those with the highest scores at baseline.\textsuperscript{196} The paradox is that patients most likely to benefit from PR appear least likely to complete it.\textsuperscript{197,198} It is important therefore to be able to identify patients with COPD who may need additional support to complete a PR program in order to broaden benefit to all.

Several mechanisms have been hypothesized to explain the effect of exercise rehabilitation on mental health symptoms. Biological mechanisms associated with exercise activity include changes in central monoamine function,\textsuperscript{199–204} enhanced hypothalamic–pituitary–adrenal axis regulation, increased release of endogenous opioids,\textsuperscript{205–207} and reduced systemic inflammation.\textsuperscript{208,209} In this way, regular physical activity may reduce depression and anxiety among patients undergoing PR. In addition, behavioral mechanisms\textsuperscript{210–215} associated with exercise activities operate synergistically to produce reductions of symptoms. Such mechanisms include active distraction from worrying thought patterns (rumination), increase of self-efficacy by providing patients with a meaningful mastery experience, and provision of daily pleasant events and regular social contact and support.

A recent systematic review\textsuperscript{216} showed that PR is beneficial in reducing anxiety and depressive symptoms, but the long-term benefit is unknown. Studies combining antidepressant pharmacotherapy or psychotherapy indicated more effective results than PR alone.\textsuperscript{217,218} Because both depression and anxiety may be manifested in physical symptoms during the course of a PR program, collaborative care is essential among all involved health-care professionals to ensure that patients’ problems are identified, evaluated, and treated.

The majority of PR programs have a primary exercise focus in order to recondition the legs and other peripheral muscles, making them more efficient as to oxygen needs, and thereby requiring relative less breathing to satisfy these oxygen requirements.\textsuperscript{219} Additionally, PR programs teach
breathing control exercises to patients and educate them in recognizing an impending dyspnea attack and preventing it, or controlling it, so they lose their fear of exerting themselves.\textsuperscript{220}

In PR settings, patients learn that they can have increases in activity levels and in dyspnea without perceiving that increase in dyspnea as a medical crisis. When patients experience their symptoms safely, they become desensitized by learning to distinguish between physical and emotional symptoms. Then, these patients can gradually take responsibility for the day-to-day management of their condition, with a result of improving their confidence, control, and autonomy.\textsuperscript{221}

PR should be offered to all COPD patients irrespective of disease severity, since they all get improvements,\textsuperscript{222,223} from mild COPD\textsuperscript{224} to severe-to-very severe lung disease.\textsuperscript{225,226} Emphasis should be given to exercise training with respect to patients with mild-to-moderate disease, but for patients with severe-to-very severe COPD, PR programs should be tailored mostly toward dyspnea management and psychological support.\textsuperscript{227,228}

In sum, the preponderance of recent evidence supports the utility of PR for reducing depression and anxiety and enhancing cognitive performance, but it is necessary to maintain the physical activity regimen to sustain the gains in physical fitness, mood, and cognitive performance, otherwise a relapse is inevitable.\textsuperscript{193} Representative studies with PR programs for COPD patients are summarized in Table 4.

**Discussion and recommendations**

Mental health problems in COPD remain underdiagnosed and undertreated.\textsuperscript{228} Although more than one-third of individuals with COPD experience comorbid symptoms of depression and anxiety,\textsuperscript{230} available evidence suggests that less than one-third of COPD patients with such comorbidity are receiving appropriate treatment for this.\textsuperscript{231} Every clinician caring for patients with COPD should have a high level of suspicion regarding the presence of mental health comorbidities since they are associated with poorer outcomes.\textsuperscript{230}

The first step to improve practice is to achieve earlier and more accurate diagnosis. It is not clear when screening should be done\textsuperscript{232,233} and if it should be carried out with all COPD patients or just to those at higher risk of these comorbidities.\textsuperscript{29} Current screening tools for anxiety and depression in patients with COPD were primarily validated for patients with other chronic diseases.\textsuperscript{234-237} The Hospital Anxiety Depression and the Beck Depression and Anxiety Inventory scales have been recommended as the preferable choice of screening tools for anxiety and depression in patients with COPD.\textsuperscript{29} Clinicians should be aware of the somatic overlap between anxiety and/or depression and COPD.\textsuperscript{238,239}

Mild-to-moderate symptoms of anxiety and/or depression should not be ignored, and treatment should be considered. High-scoring patients should be referred to a mental health specialist for a comprehensive diagnostic assessment using structured clinical interviews. It is well known that physiological, functional, and psychosocial consequences of COPD are only poorly to moderately related to each other.\textsuperscript{240} This means that a comprehensive assessment of the effects of COPD requires a battery of instruments that not only tap the disease-specific effects, but also the overall burden of the disease on everyday functioning and emotional well-being. Accurate assessment will ensure that treatment modalities are targeting the specific mental health problem taking into account individual factors, such as genetic predisposition, nicotine addiction, social support, other comorbidities, etc.

Identification of mental health problem should guide the choice of pharmacological, psychotherapeutic, or other suitable intervention (Figure 1). While treatment guidelines highlight the importance of recognizing and treating depression and anxiety in patients with COPD, there are few clear evidence-based pathways for the treatment of depression and anxiety. A GOLD report states that there is no evidence that anxiety and depression should be treated differently in the presence of COPD, so at this point of time guidelines are based on treatment of depression and anxiety for the general population.\textsuperscript{1}

In clinical practice, bidirectional associations between depression and/or anxiety and COPD imply the need to promote approaches that integrate physical and mental health care. The NICE has published clinical guidelines for managing depression in people with long-term conditions.\textsuperscript{113} The guidelines review the evidence for the associated service-level interventions (such as stepped care and collaborative care) and psychosocial, psychological, and pharmacological interventions.

According to reviews and meta-analysis,\textsuperscript{185,230} current evidence for treatment options to reduce anxiety and depression in patients with COPD include pharmacological treatments, CBT, PR, relaxation therapy, and personalized interventions.\textsuperscript{241,242} PR has extensive evidence supporting its benefits, and it has been shown to significantly reduce symptoms of both anxiety and depression in COPD patients.\textsuperscript{216} Although there is lack of strong evidence for the efficacy of pharmacological treatment in patients with COPD with comorbid depression and anxiety, adding a depression- or anxiety-targeted treatment to the PR...
program may have additive therapeutic benefits. Maximizing the efficiency of services is important as limited health resources allocated to PR programs mean that not every patient with COPD who might benefit has access to them.

In recent years, a model of care termed the collaborative-care model has been found to be associated with significant improvement in depression outcomes. Collaborative-care models that focus on building partnerships between mental health and other professionals to foster integration of care for people with complex morbidities present a fruitful framework for the management of mental health in COPD. By definition, PR is an example of a collaborative-care model. In particular, the integration of PR and psychological therapies, such as CBT, has the potential to lead to significant patient benefits. Contemporary research suggests that complex psychological and/or lifestyle interventions, which include a PR component, have the greatest effects on depression and anxiety in patients with COPD.

Most people with stable COPD are managed in primary care where recognition, assessment, and initial management of anxiety and depressive symptoms can be provided. Tailoring mental health interventions to adapt not only to the unique needs of COPD patients but also to the current primary care setting is necessary. From the earliest consultations, we should acknowledge patients’ beliefs about their COPD and its management to better assess their likely responsiveness to treatment. We can then more effectively deliver from a menu of interventions in order to improve outcomes. Continuity of care implies that when COPD patients need hospitalization for the treatment of exacerbations, mental health issues should be more systematically addressed enhancing benefit for the many not the few.

**Limitations**

Including nonrandomized studies and other reviews and meta-analyses resulted in differences to varying degrees from the typical intervention review. Reporting results in narratives impeded the drawing of statistical conclusions about the interventions’ summary effect.

**Future needs**

Future research studies should focus on:

1. Identifying which components of PR are essential, its ideal length and location (hospital-based inpatient or outpatient, or community-based, home-based), the degree of supervision and intensity of training required, how long treatment effects persist, and the barriers of PR attendance and completion in real-life PR settings.

![Figure 1](https://www.dovepress.com/)

Figure 1: Recommendations for appropriate interventions following assessment of mental health symptoms in patients with COPD.
2. Determining the best treatment for specific COPD groups, eg, based on sex, severity of COPD, frequency of exacerbations, and type and severity of comorbid mental health problems, so the efficacy of treatments in different subgroups can be assessed.
3. Disentangling the contributions of exercise training, education, and CBT in a COPD population with clear inclusion and exclusion criteria for anxiety and depression severity and adequately powered RCTs.
4. Investigate a range of treatment options in COPD across all care settings, including comparison of different treatment options and various combinations.
5. Address the cost-effectiveness and feasibility of targeted treatment of anxiety and depression, of the different interventions (eg, optimal length of therapy; when to stop treatment in nonresponders; identifying predictors of success and failure).
6. Examine novel types of disease management interventions with respect to social and behavioral principles and models most relevant for COPD patients in order to increase their engagement and improve health outcomes.247,248
7. Develop properly “evidence-based” COPD care programs that proactively address mental health in order to optimize physical and mental health outcomes.

Conclusion
Patients suffering from COPD frequently experience comorbid symptoms of anxiety and depression. Detection and recognition of these symptoms is of utmost importance as they are related to both disease progression, treatment, and rehabilitation procedures. Although the literature on treating anxiety and depression in COPD patients is limited, we believe that it points to a more multidisciplinary approach and to the implementation of personalized strategies to address both anxiety and depressive symptoms in these patients.

Disclosure
The authors report no conflicts of interest in this work.

References


